Perrigo Reports Significant Q1 Loss Driven by $330.8M Goodwill Impairment, Reaffirms Full-Year Outlook
summarizeSummary
Perrigo Company plc reported a substantial net loss of $(2.87) per share for Q1 2026, primarily due to a $330.8 million goodwill impairment charge, alongside declining net sales, but reaffirmed its full-year guidance.
check_boxKey Events
-
Q1 Net Loss Reported
Perrigo reported a net loss of $(398.6) million, or $(2.87) per diluted share, for the first quarter ended March 28, 2026, compared to a net loss of $(6.4) million in the prior year.
-
Significant Goodwill Impairment
The company recorded a $330.8 million goodwill impairment charge in Q1 2026, which was a primary driver of the reported net loss and was an expected impairment as noted in the prior 10-K.
-
Sales Decline Across Segments
Reported net sales decreased 7.2% year-over-year to $969.2 million, with Core organic net sales declining 11.0% due to lower consumption and retailer inventory levels in both the U.S. and Europe.
-
Full-Year Outlook Reaffirmed
Despite the weak first-quarter performance, Perrigo reaffirmed its full-year 2026 outlook, anticipating improvement in the second half of the year from growth initiatives and operational programs.
auto_awesomeAnalysis
Perrigo's first-quarter results reveal significant financial challenges, marked by a substantial net loss and a $330.8 million goodwill impairment, which was anticipated in the prior 10-K. The company experienced declines in both reported and core net sales, reflecting lower consumption and retailer inventory adjustments. Despite these headwinds and increased cash outflow from operations, management has reaffirmed its full-year 2026 outlook, signaling confidence in a second-half improvement driven by growth initiatives and operational enhancements. The completion of the Dermacosmetics business sale, with proceeds directed towards debt reduction, provides some financial flexibility. Investors will closely monitor the company's ability to execute its strategic plan and achieve the projected second-half recovery, especially given the ongoing operational challenges and the impact of geopolitical developments.
At the time of this filing, PRGO was trading at $12.16 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $9.23 to $28.44. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.